The Activity and Safety of First-Generation TRK Inhibitors in NTRK Fusion–Positive Cancers

Download these expert-selected slides on treating patients with NTRK-positive tumors with TRK inhibitors.
Alexander Drilon, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 472 KB
Released: June 11, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

In this on-demand webcast from CCO, Mary Jo Fidler, MD, and Scott Gettinger, MD, review the latest advances in immunotherapy for NSCLC through discussion of a series of patient cases.

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 15, 2021 Expired: July 14, 2022

Download this short slideset for an overview of the current status of biomarkers guiding optimal use of targeted therapy and immunotherapy in the treatment of advanced NSCLC, from CCO

Stephen V. Liu, MD Suresh S. Ramalingam, MD, FACP, FASCO Lecia V. Sequist, MD, MPH Released: July 8, 2021

Video from Clinical Care Options (CCO) featuring latest guidance in the diagnosis and treatment of patients with NTRK fusion positive cancers.

George D. Demetri, MD
Program Director
Alexander Drilon, MD Theodore Laetsch, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 7, 2021 Expired: July 6, 2022

Downloadable summary slideset from a live CCO Webinar on recent advances in immunotherapy for the treatment of patients with early and advanced NSCLC

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Released: July 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.